The t(10;11)(p12;q23) translocation and the t(10;11)(p12;q14) translocation, which encode the MLL (mixed lineage leukemia)-AF10 and CALM (clathrin assembly lymphoid myeloid leukemia)-AF10 fusion oncoproteins, respectively, are two recurrent chromosomal rearrangements observed in patients with acute myeloid leukemia and acute lymphoblastic leukemia. Here, we demonstrate that MLL-AF10 and CALM-AF10-mediated transformation is dependent on the H3K79 methyltransferase Dot1l using genetic and pharmacological approaches in mouse models. Targeted disruption of Dot1l using a conditional knockout mouse model abolished in vitro transformation of murine bone marrow cells and in vivo initiation and maintenance of MLL-AF10 or CALM-AF10 leukemia. The treatment of MLL-AF10 and CALM-AF10 transformed cells with EPZ004777, a specific small-molecule inhibitor of Dot1l, suppressed expression of leukemogenic genes such as Hoxa cluster genes and Meis1, and selectively impaired proliferation of MLL-AF10 and CALM-AF10 transformed cells. Pretreatment with EPZ004777 profoundly decreased the in vivo spleen-colony-forming ability of MLL-AF10 or CALM-AF10 transformed bone marrow cells. These results show that patients with leukemia-bearing chromosomal translocations that involve the AF10 gene may benefit from small-molecule therapeutics that inhibit H3K79 methylation.
INTRODUCTION
Chromosomal translocations, which encode fusion proteins, are frequently associated with human leukemias. The t(10;11)(p12;q23) translocation, which encodes the MLL (mixed lineage leukemia)-AF10 fusion protein, is a recurrent chromosomal rearrangement observed mainly in patients with acute myelogenous leukemia. 1, 2 Another translocation involving AF10, the t(10;11)(p12;q14) translocation, encodes a CALM (clathrin assembly lymphoid myeloid leukemia)-AF10 fusion protein and is observed in acute myelogenous leukemia, acute lymphoblastic leukemia and precursor T lymphoblastic lymphoma. 3 Patients with acute myelogenous leukemia harboring either MLL-AF10 or CALM-AF10 rearrangements have particularly poor outcome compared with patients whose leukemia cells do not harbor these translocations. 4 Thus, new therapeutic approaches are clearly needed for patients with AF10-rearranged hematopoietic malignancies.
Although similar motifs in the AF10 portion are retained in both MLL-AF10 as well as CALM-AF10 oncoproteins motifs, MLL and CALM are quite dissimilar proteins. The wild-type MLL protein positively regulates the expression of homeobox (Hox) genes, and is essential for hematopoietic development. 5, 6 MLL possesses multiple N-terminal domains required for target gene recognition, [7] [8] [9] which are retained in the oncogenic MLL-AF10 fusion protein. MLL also possesses a C-terminal H3 lysine 4 (H3K4) methyltransferase domain, 10, 11 which activates Hox gene expression during normal development but is absent in the fusion protein. On the other hand, wild-type CALM protein, primarily localized in the cytoplasm, is involved in clathrinmediated endocytosis and has been shown to be involved in erythropoiesis and iron metabolism. 12, 13 The clathrin binding domain on the C-terminus of CALM is always retained in the CALM-AF10 fusion proteins, and is sufficient for leukemogenesis when fused with AF10.
14 As a fusion partner of both MLL and CALM, wild-type AF10 (acute lymphoblastic leukemia-1 fused gene from chromosome 10) is a putative transcription factor containing N-terminal plant homeodomain zinc finger motifs and a C-terminal octapeptide motif-leucine zipper (OM-LZ) domain. 15 The AF10 OM-LZ domain is always retained in the MLL-AF10 and CALM-AF10 fusion proteins, and has been identified as a domain that interacts with the histone H3 lysine 79 (H3K79)-specific methyltransferase DOT1L. 16, 17 Although the mechanism by which the leukemogenic AF10 fusions transform hematopoietic cells has not been fully elucidated, it has been suggested that Dot1l interaction with the AF10 OM-LZ domain is critical for oncogenesis. 16, 18 H3K79 methylation, catalyzed solely by Dot1l, is a chromatin modification ubiquitously associated with actively transcribed genes. 19, 20 In human and mouse MLL-AF10 and CALM-AF10 leukemia cells, dimethylated H3K79 is typically enriched in the 1 promoter regions of leukemogenic genes, including the posterior Hoxa cluster genes. 16, 18 Furthermore, the epigenetic deregulation of these specific leukemogenic genes correlates with aberrant overexpression in leukemia cells. 14, 16, 18 Therefore, while DOT1L has not been found to be genetically altered in leukemia, its aberrant recruitment and/or activity may lead to epigenetic deregulation and overexpression of crucial fusion protein target genes. Consistent with this model, it has been shown that hematopoietic progenitor cells cannot be transformed by MLL-AF10 after being treated with small hairpin RNA (shRNA) against Dot1l for 1 week. 16 Moreover, bone marrow cells could not be transformed by CALM-AF10 when a dominant-negative form of Dot1l was overexpressed. 18 Although the knockdown and overexpression approaches have some limitations, these results raise the possibility that DOT1L may be a relevant therapeutic target for MLL-AF10 and CALM-AF10 leukemia. To determine whether inhibition of DOT1L represents a valid approach to treat MLL-AF10 and CALM-AF10 leukemias, we assessed the effects of genetic deletion and pharmacological inhibition of Dot1l in murine bone marrow cells immortalized by MLL-AF10 and CALM-AF10 oncoproteins. Using genetically defined models of human leukemia that bear specific epigenetic perturbations, our study demonstrates that such abnormal chromatin modifications can be specifically targeted using a small-molecule inhibitor. These observations are of particular interest in the light of mounting evidence for specific epigenetic alterations in several human tumors.
MATERIALS AND METHODS

Mutant mice
Mice engineered to harbor LoxP sites flanking exon 5 of Dot1l were generated in our laboratory and have been described previously. 21 Bone marrow cells from 7-10-week-old mice in Dot1l wild-type or homozygous floxed (Dot1l f/f ) backgrounds were used for transformation assays and subsequent biochemical experiments.
Generation of transformed murine cells and leukemia
The MSCV-based MLL-AF9-IRES-GFP, HoxA9-IRES-GFP and Meis1a-PGKPuromycin constructs were described previously. 21 The FLAG-CALM-AF10 minimal fusion construct has been described in detail earlier 14 and the FLAG-MLL-AF10 construct was generated by fusing amino acids 1-1430 of MLL to amino acid 625-1027 of AF10 in an MSCV-IRES-GFP vector. The MSCV-IRES-Tomato plasmid was a kind gift from the lab of Hassan Jumaa (Max Planck Institute, Freiburg, Germany). The cDNA for Cre recombinase was subcloned into the MIT plasmid to generate the MSCVCre-IRES-Tomato (Cre-MiTomato, or Cre) construct. Retroviral supernatants were collected from 293-T cells separately transfected with the plasmids using standard protocols and used for retroviral spin infections. Sorted Lin À Sca À 1 þ cKit þ (LSK) cells from mouse bone marrow were used for retroviral transduction experiments. The LSK cells were transduced with viruses carrying MLL-AF10, CALM-AF10, MLL-AF9, or HoxA9 and Meis1, and expanded for 2-5 days in methylcellulose M3234 (StemCell Technologies, Vancouver, BC, Canada) supplemented with cytokines (6 ng/ml IL3, 10 ng/ml IL6 and 20 ng/ml SCF). MLL-AF10 or CALM-AF10-transformed cells were then transduced with Cre or MIT and expanded in methylcellulose M3234 supplemented with cytokines. After 2 days, GFP þ Tomato þ cells were sorted for in vitro colony-forming assays, or sorted and transplanted into B6/129 syngeneic sublethally irradiated (550 rad) recipients at 5 Â 10 5 cells/mouse. For secondary transplants, whole-bone marrow from leukemic mice was isolated and transduced with Cre or MIT on the same day; GFP þ Tomato þ cells were sorted in 2 days, and transplanted into sublethally irradiated (550 rad) B6/129 syngeneic recipients at 5 Â 10 5 cells/mouse for the generation of secondary CALM-AF10 leukemia, or non-irradiated severe combined immunodeficiency recipients at 2 Â 10 5 cells/mouse for the generation of secondary MLL-AF10 leukemia.
Colony-forming assays
Colony-forming cell assays were performed by plating 1000 cells per ml of methylcellulose M3234 supplemented with cytokines (6 ng/ml IL3, 10 ng/ml IL6 and 20 ng/ml SCF). On days 6-7 after plating, colonies were scored using a Nikon Eclipse TS100 microscope (Nikon, Tokyo, Japan) and classified into two categories-compact and hypercellular blast-like colonies or small and diffuse differentiated-type colonies. Colonies were then pooled and used for biochemical assays or replated for the assessment of secondary replating potential at the same concentration. Cytospin preparations were performed from 50 000-100 000 cells. Pictures of colonies and Wright-Giemsa-stained cytospin preparations were taken using a Nikon Eclipse E400 microscope (Nikon, Tokyo, Japan) and a SPOT RT color digital camera (Diagnostic Instruments, Sterling Heights, MI, USA).
EPZ004777
EPZ004777 was synthesized by Epizyme (Cambridge, MA, USA). Stock solutions of volume 50 mM were prepared in dimethylsulphoxide (DMSO) and stored at À 20 1C. Serial dilutions of stock solutions were carried out just before use in each experiment and final DMSO concentrations were kept at or below 0.02%.
Cell Proliferation,viability assay and colony-forming unit-spleen (DCFU-S) assay
For the assessment of cell proliferation and viability, cells from three independent transductions for each virus were plated, in duplicate, in 96-well plates at a density of 1.5 Â 10 4 cells/well in a final volume of 150 ml. Cells were incubated in the presence of increasing concentrations of EPZ004777 up to 10 mM. Viable cell number was counted every 3-4 days for up to 17 days using Trypan blue staining. On days of cell counts, growth media and EPZ004777 were replaced and cells split to a density of 1.5 Â 10 4 cells/well. Results were plotted as the percentage of splitadjusted viable cells in the presence of EPZ004777 compared with DMSO vehicle control. For DCFU-S assays, cells from two independent transductions for each virus were plated in 24-well plates at a density of 1.5 Â 10 4 cells/well with 10 mM EPZ004777 or DMSO control. Growth media and EPZ004777 were replaced on day 4. On day 8, viable cells were counted and injected into lethally irradiated (550 rad twice) syngeneic recipients at 10 4 cells/mouse. After 2 weeks, mice were euthanized and spleens were collected and fixed using standard protocols.
Cell cycle and apoptosis assays MLL-AF10 and CALM-AF10 transformed bone marrow cells were plated in 12-well plates at a density of 2 Â 10 5 cells/ml. Cells were incubated with 10 mM EPZ004777 or DMSO vehicle control in a final volume of 1 ml for up to 10 days during, which media with inhibitor were changed every 3-4 days. Cell cycle analysis was performed after 30 min. of BrdU labeling using BrdU-APC/7AAD kit from BD-Pharmingen (San Jose, CA, USA) on day 0, 4, 8 and 10. Data were acquired on a 4-color Becton-Dickinson FACSCalibur flow cytometer and analyzed using BD FACS Diva (San Jose, CA, USA) and Modfit LT (Verity Software House, Topsham, ME, USA). Annexin V apoptosis assays were performed on day 10. Cells incubated with 10 mM EPZ004777 or DMSO vehicle control were washed in phosphate-buffered saline (PBS), resuspended in Ca/HEPES buffer (10 mM HEPES, pH 7.4; 140 mM NaCl; 2.5 mM CaCl 2 ) and incubated with Annexin V-PE (BioVision Inc., Mountain View, CA, USA) for 20 min. Data were acquired on a 4-color Becton-Dickinson FACSCalibur flow cytometer and analyzed using BD FACS Diva.
Western blotting and immunofluorescence
Histone purification was performed with triton extraction (1 Â PBS, 0.5% TritonX100 and 2 mM phenylmethylsulfonylfluoride) followed by acid extraction with 0.2 N HCl as previously described. 21 Whole-cell protein extracts were prepared for the detection of MLL-AF10 and CALM-AF10 fusion proteins (see supplemental data for detailed protocol). Immunofluorescence was done following a previously established protocol. 21 The following antibodies were used for detection: anti-H3K79me2 antibody ab3594 (Abcam, Cambridge, MA, USA), anti-total H3 antibody ab1791 (Abcam), anti-MLL antibody A300-086A (Bethyl Laboratories, Montgomery, TX, USA), anti-FLAG m2 antibody F1804 (Sigma-Aldrich, Saint Louis, MO, USA); secondary antibodies used: sheep anti-mouse ECL (enhanced chemiluminescence) horseradish peroxidase linked NA931V, donkey antirabbit ECL horseradish peroxidase linked NA934V (GE Healthcare UK Limited, Little Chalfont, UK), and Alexa 594-conjugated goat anti-rabbit antibody A11072 (Invitrogen, Carlsbad, CA, USA).
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Reverse transcription and real-time PCR Total RNA was isolated using Trizol (Invitrogen) according to the manufacturer's instruction. The resultant cDNA was generated using the Tetro cDNA synthesis kit (Bioline, Taunton, MA, USA 
RESULTS
H3K79me2 is abrogated by genetic inactivation of Dot1L in MLL-AF10 and CALM-AF10 transformed bone marrow cells We used a Dot1l conditional knockout mouse model, in which the exon encoding the active site of Dot1l is flanked by LoxP sites, 21 to determine whether Dot1l and H3K79 methylation are indeed required for transformation driven by MLL-AF10 and CALM-AF10. We sorted LSK cells from Dot1l þ / þ and Dot1l Figure 2d showed that 3 days after transduction, only the excised allele could be detected. However, at the end of the first round of plating (day 9), the surviving cells had various degrees of deletion, and at the end of the second round of plating (day 16), only the non-deleted allele could be detected. The fact that a small number of non-deleted cells outgrew in 2 weeks demonstrated a high selective pressure against Dot1l deleted cells. We then assessed changes in the expression of select MLL-fusion target genes in MLL-AF10-transformed bone marrow cells after the loss of Dot1l. The N-terminus of MLL binds to leukemogenic genes, including 5 0 Hoxa cluster genes and Meis1, and the binding region in MLL is retained in MLL-AF10 fusion proteins. 7, 8 The overexpression of MLL-fusion targets is a key feature of MLL-AF10 leukemia and the suppression of these leukemogenic genes, such as Hoxa9, is sufficient to abolish the leukemia. 16 As shown in Figure 2c , targets of MLL-AF10 were downregulated after Cre-mediated deletion of Dot1l, while the expression of a gene that is not an MLL-fusion target, Hoxb4, was not changed. This finding demonstrates that Dot1l is required for continued expression of MLL-AF10 target genes, which further supports the requirement of Dot1l in MLL-AF10 leukemia. We also assessed the expression changes of leukemia related genes in CALM-AF10 transformed LSK cells after the loss of Dot1l. It has been shown that leukemogenic genes, including 5 0 Hoxa cluster genes and Meis1, are overexpressed in both CALM-AF10 mouse leukemias and CALM-AF10-positive patient leukemias. 22, 23 The suppression of these leukemogenic genes, such as Hoxa5, is sufficient to abolish CALM-AF10 leukemia. 18 As shown in Figure 2c , Hoxa5, Hoxa7, Hoxa9, Hoxa10, and Meis1 were all downregulated after Cre-mediated deletion of Dot1l, while the expression of a control gene, Hoxb4, did not change (Figure 2c ). This finding demonstrates that Dot1l is required for maintenance of the transformed phenotype in cells expressing CALM-AF10.
Selective anti-proliferative effect of MLL-AF10 and CALM-AF10 transformed cells by the Dot1l Inhibitor EPZ004777 Having established that genetic inactivation of Dot1l inhibits H3K79 methylation and clonogenic potential of MLL-AF10 or CALM-AF10 transformed cells, we investigated the efficacy of Dot1l inhibitors against MLL-AF10 and CALM-AF10-transformed murine bone marrow cells. Recently it has been shown that the Dot1l inhibitor EPZ004777 selectively kills MLL-rearranged leukemia cells, including an MLL-AF4 leukemia cell line MV4-11, and an MLL-AF9 leukemia cell line MOLM13, but not MLL-germline leukemia cells, including Jurkat and HL-60. 24 However, the response of MLL-AF10 leukemia cells to a Dot1l inhibitor has not yet been evaluated, and the CALM-AF10 leukemia cell line U937 surprisingly showed minimal response to the inhibitor. 24 Therefore, we performed proliferation assays over several days with three independently-transformed mouse LSK cell populations with MLL-AF10 or CALM-AF10 in the presence of increasing concentrations of EPZ004777 (up to 10 mM) or DMSO vehicle control. MLL-AF9 transformed cells were included as a positive control, and HoxA9 and Meis1 cotransformed (HoxA9/Meis1) cells were included as a non-MLL-rearranged cell line control, which has been shown to be refractory to Dot1l inhibition. 21 As shown in Figure 3a , the growth of MLL-AF10 and CALM-AF10 cells, as well as MLL-AF9 cells, was dramatically inhibited by EPZ004777, while the growth of HoxA9/Meis1 cells was unaffected. 
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MLL-AF10 and CALM-AF10 leukemia. 16, 22, 23 We performed quantitative RT-PCR to examine the effect of EPZ004777 on Hoxa9 and Meis1 mRNA expression levels in MLL-AF10 and CALM-AF10 transformed-cells. The mRNA expression levels of Hoxa9 and Meis1 started to decrease within 3 days and became significantly lower within 7 days' treatment with 10 mM EPZ004777 (Figure 3c) . Analysis of cells on day 7 of EPZ004777 treatment showed a concentration-dependent decrease of mRNA levels of Hoxa9 and Meis1, but not b-actin, which shows that the decrease in Hoxa9 and Meis1 expression is not caused by a general inhibition of gene expression ( Figure 3d ).
Next we determined if the decrease in cell number for EPZ004777-treated MLL-AF10 or CALM-AF1-transformed cells was mostly due to inhibition of cell proliferation or induction of apoptosis. Dot1l inhibition reduced the number of actively proliferating MLL-AF10 cells, with an increase in the percentage of cells in the G1 or sub G1fractions after 4 days of incubation with 10 mM EPZ004777 (Figure 4a ). Moreover, a significant increase in the percentage of apoptotic cells after inhibition of Dot1l was observed in MLL-AF10 transformed cells compared with DMSO control on day 10 ( Figure 4b) . Similarly, Dot1l inhibition reduced the number of CALM-AF10 cells in S-phase, with the majority of cells found in G1 after 4 days of incubation with 10 mM EPZ004777 (Figure 4c ). Interestingly, there was only a minimal increase in apoptotic cells throughout the length of this experiment (Figure 4d ), suggesting the effect on CALM-AF10 may be more of a cell cycle arrest whereas MLL-AF10 cells respond with cell cycle arrest and more pronounced apoptosis.
We went on to test whether EPZ004777 treatment affects the colony-forming ability and serial replating capacity of MLL-AF10 and CALM-AF10 transformed LSK cells in in vitro colony-forming cells assays. We cultured MLL-AF10 or CALM-AF10 transformed mouse bone marrow cells in methylcellulose-based medium containing DMSO or 10 mM EZP004777. MLL-AF10 or CALM-AF10 transformed cells formed large, highly clonogenic compact blast-like colonies in methylcellulose-based medium containing DMSO. However, MLL-AF10 or CALM-AF10 transformed cells formed significantly fewer compact colonies in medium containing 10 mM EZP004777 starting from the first week (Figure 5a ). The clonogenic potential of MLL-AF10 or CALM-AF10 transformed cells was abrogated after 2 weeks culture in the presence of inhibitor. Cytospin at the end of the first week showed that the majority of EPZ004777-treated cells have large cytoplasm and small or fragmented nucleus, consistent with myeloid differentiation.
To study the effect of pharmacological inhibition of Dot1l in vivo, we pretreated MLL-AF10 and CALM-AF10 transformed cells in liquid culture with either DMSO or 10 mM EPZ004777 for 8 days before injecting into lethally irradiated recipients (Figure 5c ). Two weeks after injection, we assessed the spleen-colony-forming In contrast, cells pretreated with inhibitor failed to form any large spleen colonies, and instead formed several small and diffuse foci, similar to the colonies observed in the in vitro methylcellulose-based cultures. These effects on the DCFU-S-forming activity suggest that EPZ004777 may show in vivo efficacy against AF10-fusion transformed cells (Figure 5d ).
Dot1l is indispensible for the initiation and the maintenance of MLL-AF10 or CALM-AF10 leukemia cells in vivo
As CFU-S activity does not directly test whether Dot1l inactivation impacts full-blown leukemogenesis, we sought to assess the impact of Dot1l deletion on in vivo leukemia initiation and maintenance by the leukemogenic AF10 fusions. Dot1l f/f bone marrow cells were transformed using retroviral MLL-AF10 or CALM-AF10. In 2-3 days, Dot1l was deleted in preleukemictransformed cells through retroviral delivery of Cre-recombinase. Two days after MIT or Cre transduction, GFP þ tdTomato þ cells were sorted and injected into sublethally-irradiated recipients at 5 Â 10 5 cells/mouse. Flow cytometric analysis of mouse peripheral blood 102 days after injection showed the propagation of Dot1l Figure 1s) . This result shows that Dot1l is required for in vivo leukemogenesis of mouse bone marrow cells transformed by MLL-AF10 as well as CALM-AF10.
We then checked the effect of Dot1l deletion on established mouse leukemia cells. We collected bone marrow cells from primary MLL-AF10 or CALM-AF10 leukemia mice, performed MIT or Cre transduction, and sorted GFP þ tdTomato þ cells for injection into mice. Dot1l f/f MLL-AF10 leukemic cells caused Mac1 þ Gr1 þ secondary myeloid leukemia with a median of 81 days after transplantation, while MLL-AF10 leukemic cells lacking Dot1l failed to cause any leukemia in mice (Figures 6b and c) . Histopathology study showed massive organ infiltration of leukemic cells in mice injected with Dot1l f/f MLL-AF10 (Figure 6e) . The spleen weight of the mice injected with Dot1l f/f MLL-AF10 was significantly higher than that of the mice injected with Dot1l
-/-MLL-AF10 (Po0.01, Figure 6d ). Similar to MLL-AF10, Dot1l f/f CALM-AF10 leukemic cells resulted in an increasing population of GFP þ tdTomato þ cells in recipients' peripheral blood and ultimately caused myeloid leukemia in recipients, while Dot1l À / À CALM-AF10 leukemic cells appeared in peripheral blood initially, but disappeared from peripheral blood within 1 month (Supplementary Figure 1s) . This result shows that Dot1l is also required for the maintenance of MLL-AF10 or CALM-AF10 leukemia in vivo.
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Sub G1 Current advances in biology, biochemistry and pharmacology have raised the prospects of highly targeted therapeutics that maximize efficacy and minimize systemic toxicity. One outstanding example is targeting the fusion protein BCR-ABL kinase by imatinib in chronic myeloid leukemia. 28 In our study, we tested the efficacy of targeting Dot1l in MLL-AF10 and CALM-AF10 leukemia. We show that the small-molecular inhibitor of data that Dot1l is not absolutely required for cell proliferation. 21 Recent studies showed that although conditional knockout of Dot1l leads to pancytopenia and failure of hematopoietic homeostasis in adult mice, the toxicity did not develop until 7-8 weeks after Dot1l inactivation. 26 More importantly, in vivo administration of EPZ004777 for 2 weeks leads to the extension of survival in a mouse MLL xenograft model with minimal hematopoietic side effects. 24 These data provide further support for the continued development of DOT1L inhibitors as a potential therapeutic modality for MLL-rearranged and CALM-AF10 leukemias.
Interestingly, Daigle et al. 24 recently demonstrated that the leukemia cell line U937, which harbors the CALM-AF10 fusion, was insensitive to EPZ004777. The U937 cell line is a monocytic leukemia cell line in which the CALM-AF10 translocation was first identified in 1996, and it is the only readily available human leukemia cell line that carries the CALM-AF10 translocation. 29 The long latency of CALM-AF10 leukemia in the murine bone marrow transplantation model and incomplete penetrance in the transgenic CALM-AF10 model strongly hints at additional collaborating mutations that need to be accumulated for CALM-AF10 leukemogenesis. 22, 30 It is possible that the U937 cell line has accumulated other mutations, either during in vivo leukemogenesis or during in vitro passages, which may enable cells to circumvent the requirement of DOT1L for leukemia maintenance in vitro. The insensitivity of U937 to DOT1L inhibition is intriguing, as both circumstantial evidence from human leukemias and experimental evidence presented here and from other studies point to a key role for the DOT1L methyltransferase in AF10-rearranged leukemias. The DOT1L interacting OM-LZ domain is consistently retained in both CALM-AF10 as well as MLL-AF10 patients, and the exclusion of the OM-LZ domain completely inhibits the transforming activity of both the CALM-AF10 as well as MLL-AF10 fusions in murine models. 16, 18 Moreover, the OM-LZ domain is also the minimal portion of AF10 required for the leukemogenesis for both the aforementioned AF10 fusions.
14,31 Importantly, our study demonstrating that both Dot1l gene ablation as well as pharmacological inhibition produce potent anti-leukemic activity in the AF10-rearranged leukemias suggest that DOT1L inhibition could be an attractive therapeutic target in these diseases. Therefore, the development of a panel of other AF10-rearranged cell lines or primary human xenograft models would appear to be warranted to assess the efficacy of DOT1L inhibition on human AF10-rearranged leukemia.
We and others have recently demonstrated that leukemogenesis-mediated by a number of MLL fusions is dependent on abnormal H3K79 methylation. 16, 21, [25] [26] [27] It was shown that the Dot1l inhibition in these MLL leukemias specifically interfered with the constitutive activation of MLL-target genes, resulting in abrogation of leukemogenesis-mediated by these MLL fusions. Interestingly, even though the CALM-AF10 fusion does not involve MLL as a fusion partner, gene expression studies have shown that the transcriptional profiles of CALM-AF10 patient samples bear strong similarities with those of MLL patient samples. 23, 32 A simplistic explanation for this similarity could be the shared dependence of these fusions on aberrant H3K79 methylation for the activation of oncogenic programs. The relation between H3K79 methylation and AF10-rearranged leukemias is, however, more complicated. On one hand, aberrant H3K79 hypermethylation in MLL-AF10 and CALM-AF10 targets are required for the activation of leukemogenic transcriptional programs and the maintenance of leukemia. On the other hand, MLL-AF10 and CALM-AF10 patient samples show a global hypomethylation of H3K79, possibly because the AF10 fusions disrupt normal AF10 function. 33 Further studies will focus on the mechanisms of how abnormal H3K79 methylation patterns are established and how deregulation of a single epigenetic modification may act as a driver of leukemias with AF10 rearrangements.
Our observation that MLL-AF10 and CALM-AF10 fusions require Dot1l for initiation as well as maintenance of leukemia, strongly indicates that pharmacological inhibition of aberrant H3K79 methylation could be of potential clinical benefit in the AF10-rearranged leukemias. Future studies will determine the effect of pharmacological DOT1L inhibition on in vivo AF10-rearranged leukemias using syngenic or xenogenic leukemia models. At the moment, such studies are precluded by the poor pharmacokinetic properties of the DOT1L inhibitor used in our studies. 24 These results could help inform future clinical trials with DOT1L inhibitors.
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